ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Oxford BioMedica (OXB.LSE)
Oxford BioMedica share price today, ATLAS forecast and fair value
Healthcare · Biotechnology · London Stock Exchange · United Kingdom
£5.32▲ +0.95%
Prices as of Oct 27, 2026 · GBP
Chance of rising in 1 month
48%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Oxford BioMedica in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Oxford BioMedica
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Oxford BioMedica a 48% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between £4.77 and £5.83; in 9 out of 10, between £3.99 and £6.97. Estimated annual volatility is 62%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- £622M
- Market cap (USD)
- $829M
- 52-week high
- £9.62
- 52-week low
- £4.20
- Revenue (12 months)
- £175M
- Gross margin
- 36.2%
- Operating margin
- -26.9%
- Net margin
- -23.2%
- Beta
- 1.11
What this means
ATLAS does not publish a fair value for OXB.LSE right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks OXB.LSE has traded between £4.20 and £9.62. Today it is 44.7% below that high and 27% above its low.
Its beta is 1.11: it moves roughly in line with the market.
About the company
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide.
Want to see everything about Oxford BioMedica?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Oxford BioMedica do?
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide.
What is the chance OXB.LSE goes up next month?
48%: close to a coin flip. In half of the simulated outcomes, OXB.LSE ends the month between £4.77 and £5.83.
How big is Oxford BioMedica and what is its P/E ratio?
Oxford BioMedica's market capitalization is £622M. We do not show a P/E because it has no positive earnings to base one on.
How volatile is OXB.LSE?
ATLAS estimates annual volatility at 62%. In a typical month, half of the outcomes end between £4.77 and £5.83.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer